Clinical Trial

Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study aims to demonstrate that in subjects with symptomatic, inoperable plexiform neurofibromas associated with neurofibromatosis type 1, TQ-B3234 capsules significantly improve the objective response rate at Week 24 compared to placebo.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-07
Trial Details
NCT Number NCT07407803
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Plexiform Neurofibroma
Enrollment 177 participants
Start Date 2026-03-31
Primary Completion 2027-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-27